ALS drug wins FDA approval despite questionable data

Sep 29, 2022, 2:21 AM | Updated: 6:37 pm

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The much-debated drug for Lou Gehrig’s disease won approval by the U.S. Food and Drug Administration on Thursday, Sept. 29, 2022, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines. (Amylyx Pharmaceuticals via AP)

(Amylyx Pharmaceuticals via AP)

WASHINGTON (AP) — A much-debated drug for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.

The Food and Drug Administration approved the drug from Amylyx Pharmaceuticals based on results from one small, mid-stage study in which patients with the debilitating disease appeared to progress more slowly and survive several months longer. Typically, the FDA requires two large studies or one study with “very persuasive” survival results for approval.

“This approval provides another important treatment option for ALS, a life-threatening disease that currently has no cure,” FDA’s neurology drug director Dr. Billy Dunn said in a statement.

The drug, Relyvrio, is the third U.S.-approved medicine for amyotrophic lateral sclerosis, or ALS, which destroys nerve cells needed for basic functions like walking, talking and swallowing. About 20,000 people in the U.S. are living with the disease.

The FDA’s review has become a flashpoint in broader debates about the regulatory agency, including how flexible it should be when reviewing drugs for deadly diseases and how much weight it should give to appeals from patients and other outside voices.

“I think it demonstrates the FDA’s ability to be facile and I think it demonstrates a lot of tenacity on the part of ALS patients and advocates,” said Dr. Catherine Lomen-Hoerth, an ALS specialist at the University of California San Francisco. “The company really tried to do everything possible to get this potentially promising drug out to patients.”

Amylyx’s drug is the latest in a string of neurological drugs that have won FDA approval despite questionable effectiveness data. The agency is still facing two government probes into its approval of the Alzheimer’s drug Aduhelm last year, which has not yet been shown to slow the disease.

In an online memo summarizing its decision, the FDA said “regulatory flexibility” was appropriate for approving Relyvrio, “given the serious and life-threatening nature of ALS and the substantial unmet need.”

The latest approval followed a remarkably turbulent path, including two negative reviews by the FDA’s internal scientists, who called the company’s results “borderline” and “not persuasive.” A panel of outside advisers backed that negative opinion in March, narrowly voting against the drug.

But the FDA has faced intense pressure from ALS patients, advocates and members of Congress. In recent weeks the agency received more than 1,300 written comments from the ALS community supporting the treatment.

That outpouring helped sway the same expert panel when FDA reconvened them earlier this month to revisit Amylyx’s drug. The second time around, they backed the drug, 7-2. The vote was not binding, but it seemed to open the door for FDA approval.

Several panelists said they were also reassured by an extraordinary exchange at the meeting in which FDA’s Dr. Dunn requested — and Amylyx affirmed — that the company would voluntarily pull its drug from the market if a large, ongoing study doesn’t confirm its benefit.

That 600-patient study is expected to report results in 2024.

But experts have pointed to the many potential problems with such an informal commitment. The FDA and the company could disagree on whether the final data supports the drug; or a company that acquires the drug in the future may not feel bound by Amylyx’s pledge.

The powder-based drug is a combination of two older ingredients: a prescription medication for liver disorders and a dietary supplement associated with traditional Chinese medicine. Cambridge, Massachusetts-based Amylyx has patented the combination and says the chemicals work together to shield cells from premature death.

Some ALS patients already take both drugs separately, sometimes paying $5,000 a month for the prescription component, according to physicians. FDA approval is expected to compel insurers to cover Amylyx’s medication.

Amylyx did not immediately disclose the price Thursday but said it planned to announce the information on a call with investors Friday morning. In Canada, where the drug received approval in June, the company has proposed a price equating to $165,000.

One outside group that analyzes the cost effectiveness of new treatments pegged the drug’s value at between between $9,100 and $30,700 per year. The Institute for Clinical and Economic Review also noted that many patients are expected to take Amylyx’s drug in combination with an older therapy, which costs over $170,000 per year.

Sunny Brous was diagnosed with ALS in 2015 and hopes to add Relyvrio to the two older FDA-approved medications she already takes for the disease.

“I’ve made it this far without this drug and I’m hoping having it now will extend my life further,” said Brous, who is 35 and lives near Fort Worth, Texas.

Amylyx’s data came from a 6-month study in 137 patients that showed some benefit in slowing the disease, based on functionality questionnaires completed by patients. Patients who continued taking Relyvrio after the study concluded appeared to survive longer than patients who originally received a placebo, the FDA noted.

“The ALS community has proven that our advocacy can impact decisions that are being made about our health,” said Larry Falivena, an ALS Association board member who was diagnosed with the disease in 2017, in an emailed statement. The group invested $2.2 million in Amylyx’s early research and stands to recoup $3.3 million from drug sales.

___

Follow Matthew Perrone on Twitter: @AP_FDAwriter

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

AP

FILE - A Boeing 747-8, Boeing's new passenger plane, takes its first flight, Sunday, March 20, 2011...
Associated Press

Boeing’s last 747 to roll out of Washington state factory

After more than half a century, Boeing is set to roll its last 747 out of a Washington state factory on Tuesday.
1 day ago
Dissident Chinese artist and activist Ai Weiwei poses for a photo in the garden of his country hous...
Associated Press

Dissident artist Weiwei says China unrest won’t alter regime

MONTEMOR-O-NOVO, Portugal (AP) — Dissident Chinese artist and activist Ai Weiwei is taking heart from recent public protests in China over the authorities’ strict COVID-19 policy, but he doesn’t see them bringing about any significant political change. “I don’t think that’s possible,” he told The Associated Press in an interview at his home in Portugal. […]
1 day ago
Tesla electric vehicles are displayed during a public launching event Wednesday, Dec. 7, 2022, in B...
Associated Press

Tesla launches in Thailand, vying to compete with China EVs

BANGKOK (AP) — Tesla has launched sales in Thailand, offering its popular Model 3 and Model Y at prices aimed at competing with rivals like China’s BYD. The company staged a glitzy showcase of its plans Wednesday at Bangkok’s Siam Paragon mall. Online purchases have begun, with plans to deliver vehicles to buyers in the […]
1 day ago
The mother and father of a four-month-old baby that urgently needs a heart operation leave the High...
Associated Press

New Zealand court rules against anti-vax parents of ill baby

WELLINGTON, New Zealand (AP) — A New Zealand court temporarily took away medical custody of a baby from his parents on Wednesday after they refused blood transfusions for him unless the blood came from donors who were unvaccinated against COVID-19. The court’s ruling in favor of health authorities places the 4-month-old boy into the guardianship […]
1 day ago
A sunken vehicle sit in the Mesaieed sea-line at the GMC dive site in Mesaieed, Qatar Wednesday, No...
Associated Press

AP PHOTOS: World Cup fans explore Qatar’s artificial reefs

MESAIEED, Qatar (AP) — Thirty feet (9 meters) deep into the waters of the Persian Gulf, angel fish swim in and out of rusted trucks and SUVs. Plastic bags and water bottles, blown in from the nearby shoreline, float across the ocean floor. World Cup fans in Qatar hoping to see some of the Gulf’s […]
1 day ago
Passengers and railway staff are seen at the scene of a train collision in Montcada i Reixac, Spain...
Associated Press

Train collision in Spain hurts 155, no serious injuries

BARCELONA, Spain (AP) — Two passenger trains taking commuters to the city of Barcelona collided early Wednesday, injuring more than 150 people, Spanish officials said. Officials reported no serious injuries. Emergency services said a total of 155 people were attended to by medics on site, with 14 later taken to medical centers for further treatment. […]
1 day ago

Sponsored Articles

Comcast Ready for Business Fund...
Ilona Lohrey | President and CEO, GSBA

GSBA is closing the disparity gap with Ready for Business Fund

GSBA, Comcast, and other partners are working to address disparities in access to financial resources with the Ready for Business fund.
SHIBA WA...

Medicare open enrollment is here and SHIBA can help!

The SHIBA program – part of the Office of the Insurance Commissioner – is ready to help with your Medicare open enrollment decisions.
Lake Washington Windows...

Choosing Best Windows for Your Home

Lake Washington Windows and Doors is a local window dealer offering the exclusive Leak Armor installation.
Anacortes Christmas Tree...

Come one, come all! Food, Drink, and Coastal Christmas – Anacortes has it all!

Come celebrate Anacortes’ 11th annual Bier on the Pier! Bier on the Pier takes place on October 7th and 8th and features local ciders, food trucks and live music - not to mention the beautiful views of the Guemes Channel and backdrop of downtown Anacortes.
Swedish Cyberknife Treatment...

The revolutionary treatment of Swedish CyberKnife provides better quality of life for majority of patients

There are a wide variety of treatments options available for men with prostate cancer. One of the most technologically advanced treatment options in the Pacific Northwest is Stereotactic Body Radiation Therapy using the CyberKnife platform at Swedish Medical Center.
Work at Zum Services...

Seattle Public Schools announces three-year contract with Zum

Seattle Public Schools just announced a three-year contract with a brand-new company to the Pacific Northwest to assist with their student transportation: Zum.
ALS drug wins FDA approval despite questionable data